Download This PaperA Modest but Meaningful Decision for Indian Drug Patents
The Lancet 384:477-479, 2014
3 Pages Posted: 15 Mar 2016
Date Written: August 9, 2014
Abstract
On April 1, 2013, the Indian Supreme Court released its long-awaited decision on Novartis AG v Union of India & Others, better known as the Glivec (Gleevec in the USA; imatinib mesylate) patent case.1 Although neither the resounding victory for access to medicines that activists celebrated nor the terminal defeat that Novartis complained about, the Court’s decision will shape India’s burgeoning medicine market in coming decades.
Suggested Citation: Suggested Citation
Attaran, Amir and Attaran, Amir, A Modest but Meaningful Decision for Indian Drug Patents (August 9, 2014). The Lancet 384:477-479, 2014, Available at SSRN: https://ssrn.com/abstract=2747623
University of Ottawa - Common Law Section ( email )
57 Louis Pasteur Street
Ottawa, K1N 6N5
Canada
613-562-5800 ext: 2015 (Phone)
613-562-5659 (Fax)
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.